Rego-SARC: Activity and safety of regorafenib (RE) in patients with metastatic soft-tissue sarcoma (STS) previously treated with anthracyclin-based chemotherapy—A multinational, randomized, placebo-controlled phase II trial.
Stephanie Clisant
No relevant relationships to disclose
Nicolas Penel
Research Funding - Bayer
Bernadette Lieg-Atzwanger
No relevant relationships to disclose
Viktor Gruenwald
No relevant relationships to disclose
Ferdinand Ploner
No relevant relationships to disclose
Sophie Taieb
No relevant relationships to disclose
Marie Vanseymortier
No relevant relationships to disclose
Axel Le Cesne
No relevant relationships to disclose
Wolfgang Eisterer
No relevant relationships to disclose
Olivier Mir
No relevant relationships to disclose
Antoine Italiano
No relevant relationships to disclose
Pierre Arvis
Employment or Leadership Position - Bayer
Andrew Kramar
No relevant relationships to disclose
Jean-Yves Blay
No relevant relationships to disclose
Thomas Brodowicz
Research Funding - Bayer